GlassScriptPhysician profile
Dana J Wallace
NPI 1659548543
$26,631.05
in general payments reported to CMS, 2019-2025
31 companies · $3,482 in 2025
The $3,482 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,413 · 2020: $829 · 2021: $1,702 · 2022: $10K · 2023: $2,513 · 2024: $5,688 · 2025: $3,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,793 · Consulting Fee: $2,100 · Travel and Lodging: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,793.37 |
| Consulting Fee | $2,100.00 |
| Travel and Lodging | $789.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $8,117.56 | 2019-2022 | |
| Glaukos Corporation | $4,630.94 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr, Idose |
| Alcon Vision LLC | $4,487.47 | 2019-2025 | Clareon, Lensx, Rocklatan |
| Abbvie INC. | $2,405.59 | 2022-2025 | Durysta |
| Johnson & Johnson Surgical Vision, INC. | $1,397.22 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Sight Sciences, INC. | $1,072.37 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Sun Pharmaceutical Industries INC. | $644.51 | 2019-2024 | Cequa |
| Coopervision INC. | $500.00 | 2021-2022 | |
| New World Medical,INC. | $492.89 | 2023-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Harrow Eye, LLC | $364.88 | 2023-2025 | Vevye |
| Bausch & Lomb Americas INC. | $345.76 | 2023-2025 | Miebo, Vyzulta, Ic-8 Apthera Iol |
| Eyepoint US, INC. | $267.21 | 2019 | |
| Rxsight INC | $247.53 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $217.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $203.92 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $182.44 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $171.55 | 2021 | |
| Ivantis, INC | $171.45 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $118.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $110.28 | 2021 | |
| Shire North American Group INC | $94.57 | 2019 | |
| Amgen INC. | $85.18 | 2024-2025 | Tepezza |
| Grifols USA, LLC | $57.62 | 2024 | Xembify |
| Oyster Point Pharma, INC. | $54.41 | 2022-2025 | Tyrvaya |
| Horizon Therapeutics Plc | $52.54 | 2023 | Tepezza |
| Thea Pharma INC. | $44.79 | 2022-2023 | |
| Genentech USA, INC. | $33.07 | 2025 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $24.94 | 2025 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $14.49 | 2022 | |
| Ocular Therapeutix, INC. | $13.06 | 2023 | Dextenza |
| Iridex Corporation | $7.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.